logo-loader
Proactive logo live
cancer Faron Pharmaceuticals focused on fighting cancers via novel immunotherapies

What it does Faron Pharmaceuticals Oy (LON:FARN)(NASDAQFIRSTNORTH:FARON) is a Finnish drug...

17 hours, 56 minutes ago
Big caps

Rolls-Royce, easyJet, Tesco: UBS’ 2024 top stock picks

Rolls-Royce Holdings PLC (LSE:RR.), easyJet PLC and Tesco PLC (LSE:TSCO) have received backing...

3 days, 16 hours ago
Small caps

Faron Pharma data readout should provide more clarity - broker

Faron Pharmaceuticals Limited (AIM:FARN) will release updated results from its BEXMAB clinical...

3 days, 19 hours ago
Big caps

AstraZeneca Amolyt Pharma takeover ‘sufficiently modest’ - analysts

AstraZeneca PLC (LSE:AZN)’s £780 million takeover of France-based Amolyt Pharma on Thursday...

3 days, 19 hours ago

Faron Pharmaceuticals reports promising phase 1 results from BEXMAB study

Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndrome (MDS) patients...

20 hours, 1 minute ago

Join Proactive

Get ahead of the curve